Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF)
Refereed conference paper presented and published in conference proceedings


Times Cited
Altmetrics Information
.

Other information
All Author(s) ListChan HLY, Buti M, Flisiak R, Ryder S, Streinu-Cercel A, Flaherty JF, Gaggar A, Mo SY, Subramanian GM, Zoulim F, Andreone P, Marcellin P
Name of ConferenceInternational Digestive Disease Forum
Start Date of Conference09/06/2018
End Date of Conference10/06/2018
Place of ConferenceHong Kong
Country/Region of ConferenceHong Kong
Proceedings TitleGUT
Title of PublicationGUT
Year2018
Month6
Volume Number67
Issue NumberSuppl 2
PublisherBMJ PUBLISHING GROUP
PagesA97 - A97
ISSN0017-5749
eISSN1468-3288
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesGastroenterology & Hepatology;Gastroenterology & Hepatology

Last updated on 2020-29-06 at 04:11